Original Article
Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma

Zhoulei Li, Ken Herrmann, Sabine Pirsig, Kathrin Philipp-Abbrederis, Martin Henninger, Michaela Aichler, Annette Feuchtinger, Axel Walch, Ambros J Beer, Ingo Ringshausen, Kelsey L Pomykala, Klemens Scheidhauer, Markus Schwaiger, Ulrich Keller, Andreas K Buck

1 Department of Nuclear Medicine, Technische Universität München, Ismaninger Strasse 22, D-81675 Munich, Germany; 2 Department of Nuclear Medicine, Universität Würzburg, Oberdörrbacher Strasse 6, D-97080 Würzburg, Germany; 3 Department of Internal Medicine III, Technische Universität München, Ismaninger Strasse 22, D-81675 Munich, Germany; 4 Institute of Pathology, Helmholtz Zentrum München and Technische Universität München, Ismaninger Strasse 22, D-81675 Munich, Germany; 5 Division of Ahmanson Translational Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University California Los Angeles, 10833 Le Conte Avenue, Room AR-249 CHS, Los Angeles, CA 90095-1782, USA

Received September 22, 2013; Accepted November 19, 2013; Epub December 15, 2013; Published January 1, 2014

Abstract: The role of [18F]fluorodeoxyglucose ([18F]FDG) PET in staging of sarcoma is well established. The aim of this preclinical study was to compare [18F]fluorothymidine ([18F]FLT) PET to [18F]FDG PET regarding early metabolic changes of sarcoma in the course of targeted cancer therapy. SCID mice bearing sarcoma A673 xenotransplants were used for investigation of tumor response after treatment with the multikinase inhibitor Sorafenib. [18F]FLT and/or [18F]FDG-PET were performed prior to and early after initiation of treatment. Tumoral uptake (% Injected Dose per gram (%ID/g) of [18F]FLT-PET was compared to [18F]FDG-PET. Results were correlated with histopathology and in vitro data including cellular uptake, cell cycle-related protein expression, cell cycle distribution and apoptosis. In vitro experiments showed that A673 cells were sensitive to Sorafenib. In vivo, tumor growth was inhibited in comparison to a 4-fold increase of the tumor volume in control mice. Using [18F]FDG as tracer, a moderate reduction in tracer uptake (n=15, mean relative %ID/g 74%, range 35%-121%, p=0.03) was observed. The decrease in %ID/g using [18F]FLT-PET was significantly higher (p=0.003). The mean relative %ID/g in [18F]FLT uptake on day + 5 was significantly reduced to 54% compared to baseline (n=15, range 24%-125%, SD=29%). The PET analysis 24 hr after therapy showed a significant reduction of the mean [18F]FLT-%ID/g (p=0.04). The reduction of %ID/g on day + 1 in [18F]FDG-PET was not statistically significant (p=0.99). In conclusion, both [18F]FDG- and [18F]FLT-PET were able to predict response to Sorafenib treatment. In contrast to [18F]FDG-PET, [18F]FLT-PET was more predictive for very early response to treatment.

Keywords: Molecular imaging, sarcoma, PET, proliferation, [18F]FLT, [18F]FDG

Introduction
Ewing Sarcoma is a malignant small round cell tumor of the musculoskeletal system and ranks as the 2nd most frequent bone related cancer in children and young adults. In the past few decades, long-term patient survival has considerably improved as a result of the success of multimodal therapeutic regimens, including surgery, chemotherapy, and radiotherapy. Today, the 10-year survival rate has reached approximately 50%. However, patients with metastatic disease have a poor prognosis. 30-40% of patients with local disease and approximately 80% of patients with metastatic disease will die because of disease progression [1-3]. In addition, long-term survival can be compromised by late side effects of chemotherapy and radiotherapy.

New insights into the molecular pathogenesis of human cancer have led to the identification of several proteins acting as signaling molecules and modulators of tumor growth. Targeting these proteins using novel pharmacologic agents can be effectively used to control tumor
Molecular imaging for sarcoma response assessment

growth [4]. Sorafenib, a small-molecule multikinase inhibitor, is a potent inhibitor of RAF kinase in vitro. Sorafenib is also a strong inhibitor of vascular endothelial growth factor (VEGF) receptor 1, 2, and 3, platelet derived growth factor (PDGF) b-receptor, c-kit, and RET. Sorafenib demonstrates antitumor activity in a broad range of human xenograft animal models including colon, mammary, pancreatic, ovarian cancer, hepatocellular carcinoma [5, 6] and sarcoma [7].

To assess therapy response, noninvasive imaging modalities like computed tomography (CT), magnetic resonance imaging (MRI) or bone scintigraphy are commonly used [8-10]. Due to the fact that a change in lesion size is mostly observed several weeks after the start of chemotherapy, other staging techniques such as PET with the radiopharmaceutical [18F]fluorodeoxyglucose ([18F]FDG), complemented with CT are widely used. [18F]FDG-PET/CT has the potential to provide an accurate assessment of early response to treatment, with the ultimate goal of identifying responding and non-responding tumors and of tailoring therapy according to the information obtained by non-invasive imaging [11-13].

Various forms of infection, inflammation, granulomatous disease and many other physiological or pathological conditions also utilize [18F]FDG and are the major cause of false-positive results [14]. While both [18F]FDG and [18F]fluorothymidine ([18F]FLT) are very sensitive markers, [18F]FLT-PET is expected to be more specific for tumor assessment [15, 16]. Shields et al. [17] first reported the potential utility of [18F]FLT for the non-invasive detection of cell proliferation by PET. [18F]FLT undergoes monophosphorylation to [18F]FLT phosphate catalyzed by the cytosolic enzyme thymidine kinase 1 (TK1), which, being cell cycle regulated, provides a surrogate measure of cells in S phase of the cell cycle [18, 19]. Thus, changes in [18F]FLT uptake can be correlated directly with cell proliferation and [18F]FLT-PET could be a potentially effective method to monitor early response to targeted therapy in the setting of clinical studies [20, 21].

In this report, severe combined immunodeficient (SCID) mice bearing A673 sarcoma xenotransplants were treated with Sorafenib. Small animal PET-CT imaging using [18F]FDG and [18F] FLT as tracers was applied to predict response to targeted therapy very early in the course of treatment.

Materials and methods

Cell lines and animal model

The cell line A673 derived from a patient with Ewing sarcoma (ATCC CRL-1598, LGC Standards GmbH, Wesel, Germany) was cultured in DMEM medium (Biochrom, Germany) containing 10% fetal bovine serum. Six to eight week old female immunodeficient mice (CB-17 SCID) were obtained from Charles River Laboratories. For induction of tumors 5×10⁶ A673 cells suspended in sterile PBS (100 µl) were injected subcutaneously into the right shoulder region. All animal experiments were authorized by the regional government agency.

Inhibitors and drugs

Sorafenib was solubilized in DMSO to 200 µM or 1 µM stock solution, respectively, for in vitro treatment, and stored at -20°C. The primary solution was diluted to 0-1000 µM with DMEM cell culture medium. Doxorubicin (Sigma-Aldrich Chemie GmbH, Munich, Germany) was diluted to 0-250 µM with DMEM cell culture medium.

MTT assay

MTT assays were performed according to the manufacturer’s instruction (Promega GmbH, Mannheim, Germany). Briefly, 10⁳ cells per well (96-well plate) were incubated at 37°C with different concentrations of inhibitors for 48 h. 20 µl of MTT dilution (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide in PBS) was added to each well and cells were incubated for 90 min. Absorbance was measured at 570 nm using a Bio-Tek ELx800 series universal microplate reader (Progen Scientific, London, UK).

Flow cytometry

Sarcoma cells (5×10⁵ per well, 12-well plates) were incubated with different inhibitor concentrations at 37°C. After 48 h, cells were centrifuged (1.700 spins/min, 7 min) and washed with cold PBS buffer (0°C). To assess cell cycle distribution, 1×10⁶ cells were stained with FITC-BrdU (BD Pharmingen, Heidelberg, Germany) and counterstained with propidium iodide (Sigma-Aldrich Chemie GmbH, Munich, Germany) and 7-AAD (BD Pharmingen, Heidelberg, Ger-
Molecular imaging for sarcoma response assessment

To assess apoptosis, 1×10⁶ cells were stained with Annexin V (BD Pharmingen, Heidelberg, Germany) and counterstained with propidium iodide (Sigma-Aldrich Chemie GmbH, Munich, Germany). Finally, cells were resuspended in 500 μl PBS and analyzed by flow cytometry (Beckman Coulter GmbH, Krefeld, Germany).


Sarcoma cells (5×10⁵ per well) were plated in 12-well plates and were incubated with different concentrations of inhibitors at 37°C for 48 h. After cell counting, 100 μl of tracer solution was added and incubated for 45 min at 37°C. Tracer solution consisted of 0.9% sodium chloride and [1⁸F]FLT or [1⁸F]FDG with an activity of 370 kBq. Cells were then washed three times with PBS before measuring activity (counts per minute, cpm) using an automated gamma-counter (WALLAC 1480 WIZARD 3, PerkinElmer, Rodgau, Germany). Results were adjusted to 10⁶ cells per well.

Tumor volume and therapeutic regimens

The tumor diameters were measured daily with a shifting calliper and tumor volume was calculated using the formula \(\text{length} \times (\text{width})^2 / 2\). Treatment was performed when the xenotransplants reached a size of approximately 100 mm³. Sarcoma bearing animals were treated daily by intraperitoneal injection of Sorafenib (30 mg/kg bodyweight). The control group received PBS only.

PET-imaging

[1⁸F]FLT and [1⁸F]FDG were synthesized as previously described [22] and were obtained from the radiopharmacy unit of the TU Munich. Imaging was performed using a dedicated micro PET/CT system (Inveon, SIEMENS Preclinical Solutions), [1⁸F]FLT or [1⁸F]FDG was administered via tail vein injection (100 μl) at an activity dose of 5-10 MBq per mouse. The accumulation of radiotracer in the tumor was allowed for 45 min. Mice were then imaged for a 15 min (static data acquisition).

PET data analysis

% Injected Dose per gram (%ID/g) were calculated to semi-quantitatively assess the tracer accumulation in the tumor. Circular 3D regions of interest (ROIs) were placed manually in the area with the highest tumor activity. The diameter was not covering the entire tumor volume to avoid partial volume effects. For determination of background activity, two 3D ROIs were placed in the spinal muscle at the level of the kidneys.

Histological and immunohistochemical analysis

Formalin-fixed, paraffin-embedded sections (5 μm) of resected tumor tissue were dewaxed, rehydrated and microwaved for 30 min in a 0.01 M citrate buffer, pH 6.0 containing 0.1% Tween 20. Sections were washed in Tris-buffered saline (pH 7.6) containing 5% fetal calf serum (Life Technologies GmbH, Darmstadt, Germany) for 20 min. The primary antibodies used were: anti-Ki67 antigen antibody solution (MIB-1, M7240, Dako; 1:75 diluted with Antibody Diluent (Dako ChemMate, Dako Deutschland GmbH, Hamburg, Germany), anti-cleaved caspase-3 rabbit monoclonal antibody solution (Asp175, Cell Signaling Technology, New England Biolabs GmbH, Frankfurt am Main, Germany). The remainder of the procedure was performed on the automated immunostainer (DISCOVERY XT, Ventana Medical System, Roche, Mannheim, Germany). Diaminobenzidine (DAB, Ventana Medical Systems, Roche, Mannheim, Germany) served as chromogen.

Statistical analysis

Statistical analyses were performed using the statistical function of Excel 2007 (Microsoft) or GraphPad Prism 5 (GraphPad Software). A \(p\)-value<0.05 was considered statistically significant, as assessed by t-test.

Results

A673 sarcoma is sensitive to Sorafenib and doxorubicin treatment in vitro

Using MTT assays, A673 sarcoma cells showed sensitivity to Sorafenib with 50% inhibition of cell viability of less than 20 μM (Figure 1A left panel). Doxorubicin inhibited the viability of A673 cells with a concentration between 100 and 500 μM (Figure 1A right panel). BrdU staining revealed that both drugs induced cell cycle arrest and cell death as demonstrated by a significant decrease of the S phase fraction as
Molecular imaging for sarcoma response assessment

well as a marked increase of the G0/G1 (Figure 1B). Furthermore, treatment resulted in apoptotic cell death (Figure 1C).

[18F]FDG and [18F]FLT uptake in vitro is a measure for viability and proliferation upon Sorafenib and doxorubicin treatment

To estimate whether multikinase targeted treatment with Sorafenib was assessable by measuring [18F]FDG and [18F]FLT uptake, we determined the cellular tracer uptake of [18F]FLT and [18F]FDG in Sorafenib treated cells. A673 cells were incubated with [18F]FLT or [18F]FDG for 45 min after a 48 hr Sorafenib treatment period and the activity was measured using a gamma-counter. As shown in Figure 2A, Sorafenib treatment led to a significant reduction of both [18F]FLT and [18F]FDG uptake in A673 cells. However, sensitivity of [18F]FLT was significantly higher showing a strong reduction of [18F]FLT uptake in the presence of 10 μM Sorafenib (23%, SD=0.13). In contrast, [18F]FDG uptake remained at 52% of untreated control at the same dose level. As a control we included the antitumoral doxorubicin, an established cornerstone drug in Ewing sarcoma protocols [23, 24]. The response as assessed by [18F]FLT and [18F]FDG uptake in A673 cells was also detected under doxorubicin treatment. As depicted in Figure 2B, response monitoring revealed superiority of [18F]FLT (10 μM: 93%, SD=6.6; 50 μM: 84.9%, SD=10.7) over [18F]FDG (10 μM: 111.6%, SD=3; 50 μM: 102.8%, SD=9.4) as early as 24 hr after Doxorubicin treatment. These data suggest that [18F]FLT uptake is more sensitive to determining very early treatment effectiveness in vitro.


To evaluate [18F]FDG- and [18F]FLT-PET imaging for response monitoring in vivo, we generated
xenograft A673 tumors. To mimic the clinical situation treatment was initiated once the tumor volume reached approximately 100 mm³. The control group showed a 4-fold (n=7, SD=2-fold, range 2-9-fold) increase in tumor volume at day 7 (Figure 3A). In contrast, tumors of Sorafenib treated mice remained basically stable during the treatment period (range 0.2 cm³-0.3 cm³, SD=0.2 cm³) at d + 7. To determine the predictive value of very early functional imaging for response assessment we performed [18F]FDG- and [18F]FLT-PET scans using a micro PET/CT system before and six days after initiation of Sorafenib treatment. To quantify tracer uptake, the change of %ID/g on day 6 compared to pre-treatment %ID/g was calculated (relative %ID/g). The relative mean %ID/g of [18F]FLT uptake decreased significantly to 54% compared to baseline (n=15, mean=54%, SD=29%, range 24%-125%, p=0.003) 5 days after initiation of therapy. The mean %ID/g of pre- and post-treatment were 12.9 (range 4.5-21.5, SD=5.8) and 5.7 (range 3.9-8.5, SD=1.4), respectively (Figure 3B). The relative [18F]FLT %ID/g of untreated controls increased to 234% during the same time period (n=5, SD=70%, range 151%-294%). [18F]FDG-PET analysis of control animals revealed a significant increase in [18F]FDG uptake on day 6. In Sorafenib treated animals, relative %ID/g of [18F]FDG-PET showed a significant reduction compared to the pre-treatment [18F]FDG-PET (n=15, mean 74%, SD=32%, range 35%-121%, p=0.03). The mean %ID/g of pre- and post-treatment are 12.8 (range 7-20.4, SD=4.5) and 8.4 (range 5-12.9, SD=2.6), respectively (Figure 3C). To correlate the PET findings with the treatment effects of Sorafenib on A673 xenograft sarcoma in vivo, we stained fixed tumor sections for the S phase marker Ki67 and cleaved Caspase-3 to analyze proliferation and apoptosis. Sorafenib treatment led to a significant increase in apoptosis as quantified by cleaved Caspase-3 positive cells (Figure 3D, n=6, mean=12%, SD=5%) compared to untreated mice (n=6, mean=6%, SD=2%, p=0.04). Moreover, the percentage of proliferating cells was substantially decreased by Sorafenib as measured by Ki67 staining with a mean of 42% (n=9, range 12%-61%) for the control and 22% (7%-47%) for the treated tumors (p=0.029). These immunohistochemical analyses confirm that the observed changes in PET tracer uptake are associated with Sorafenib effects on sarcoma growth and survival. To assess very early therapy response mice bearing A673 xenograft tumors underwent PET imaging before a significant change of tumor volume at d + 1 after start of treatment. Again, treatment was started when mice had measurable xenograft tumors. As depicted in Figure 4A, tumor growth did not differ significantly between treated and control animals (p=0.2). [18F]FLT-PET was able to significantly discriminate between post-treatment (%ID/g=7.6, SD=0.8) and pre-treatment uptake (%ID/g=14.2, SD=4.8) with a reduction to 57% (n=4, SD=14%, range 44%-71%, p=0.04) (Figure 4B, right panel). In contrast, using [18F]FDG-PET it was not possible to detect a significant change in tracer uptake (n=3, p=0.99). The mean %ID/g of pre- and post-treatment are 14.0 (range 10.1-16.8, SD=3.5) and 14.0 (range 12.6-16.4, SD=2.1), respectively (Figure 4C, right panel). In summary, both [18F]FDG and [18F]FLT are useful to detect treatment res-posne, but only [18F] FLT-PET predicts response immediately after treatment initiation.
Molecular imaging for sarcoma response assessment

Discussion

In this preclinical study, we explored whether PET imaging of tumor proliferative activity using $^{18}$F-FDG and $^{18}$F-FLT can provide treatment response assessment in sarcoma cell lines and mice bearing sarcoma A673 xenotransplants. Both $^{18}$F-FDG as well as $^{18}$F-FLT uptake correlates with response to Sorafenib therapy in vivo. However, the reduction of %ID/g in $^{18}$F-FLT-PET was significantly more pronounced compared to that in $^{18}$F-FDG-PET. In particular, there was no significant difference in tracer uptake imaged by $^{18}$F-FDG at day + 1 after treatment initiation, while $^{18}$F-FLT-PET imaging showed a significant change in tracer uptake. Thus, our study provides strong evidence that $^{18}$F-FLT-PET is highly suitable to predict very early response to Sorafenib therapy in vivo. Considering the overall moderate efficacy that has been shown in sarcoma treated with small molecule kinase inhibitors, the immediate identification of non-responders or the benefiting patients would be of immense clinical importance [25, 26].

Non-invasive molecular or functional imaging using PET allows for biological processes to be visualized and quantified non-invasively over time. $^{18}$F-FDG is currently the most widely used radiotracer for imaging in oncology and proved useful for detecting and staging cancer [12, 27, 28]. Several studies have analyzed changes in $^{18}$F-FDG uptake following anti-cancer treatment, but with variable results [29, 30]. $^{18}$F-FLT is used as a PET tracer for visualization of cell proliferation [17] and a correlation between $^{18}$F-FLT uptake and tumor cell proliferation in mouse xenografts and humans was previously shown [13, 15, 31-34]. The
Molecular imaging for sarcoma response assessment

Functional in vivo imaging of A673 inhibition with $^{18}$F-FLT-PET is superior to $^{18}$F-FDG-PET. Mice were treated with Sorafenib ($n=7$, 30 mg/kg i.p. daily) or PBS solution ($n=7$, i.p. daily) when xenotransplants reached a volume of approximately 100 mm$^3$ (day 0). (A) Tumor volume did not change after 24 h Sorafenib treatment in therapeutic group (p=0.2). $^{18}$F-FLT- (B) and $^{18}$F-FDG-PET (C) was performed before (day 0) and 24 h after initiation of therapy. Left panels: representative PET scans showing change of tumor tracer uptake (arrows). Right panels: tracer uptake, before and after treatment, was calculated. Mean %ID/g of $^{18}$F-FLT-PET (p=0.04) was significantly reduced in contrast to %ID/g of $^{18}$F-FDG-PET (p=0.99).

The present study provides further evidence that $^{18}$F-FLT-PET represents a superior readout also for monitoring response in sarcoma of soft tissue or bone. Similarly, McKinley and coworkers showed in preclinical models of colorectal cancer cell lines that $^{18}$F-FLT-PET may be superior to $^{18}$F-FDG-PET for quantifying clinical response to targeted therapy [36]. $^{18}$F-FLT-PET also predicts response to $\text{V600E}^{\text{BRAF}}$-targeted therapy in preclinical models of colorectal cancer. Compared to $^{18}$F-FDG-PET, $^{18}$F-FLT-PET provides higher specificity and may be a more suitable option to evaluate response in clinical settings, in particular when used for response assessment very early in the course of therapy. Another approach is to directly radiolabel the therapeutic compound. Recently radiolabelling of Sorafenib has been described, facilitating the estimation of the bioavailability of the drug and direct assessment of response to treatment [37]. Due to the limited availability of cyclotrons capable of providing $^{13}$C and the need for more sophisticated imaging protocols, PET using $^{13}$C-Sorafenib as the tracer will hardly be included in the therapeutic management of cancer patients in the near future.

Very early non-invasive and reliable response assessment is highly desirable for the management of cancer patients.
Molecular imaging for sarcoma response assessment

This issue has become even more demanding with a plethora of novel small molecule therapeutics entering preclinical and clinical testing [25, 26]. Currently, interim staging is mainly performed by CT, MRI or ultrasonography usually 6 to 8 weeks after initiation of therapy. Small molecule anti-cancer agents may be of immense clinical benefit by stabilizing the disease, and conventional assessment by morphology-based criteria could be misleading to assess effectiveness and clinical benefit [30, 38]. It is therefore of foremost importance to further develop novel methods for assessing clinical response besides tumor volume shrinkage.

In vitro experiments with A673 sarcoma cells and Sorafenib or doxorubicin confirmed that sensitivity of [18F]FLT-PET for detecting early changes of tumor metabolism is significantly higher, as compared to [18F]FDG. These results are in line with a previous trial, where we showed that the classical cytotoxic drug doxorubicin led to dose-dependent reduction in [18F] FLT-uptake in lymphoma cells, in contrast to a variable and slower reduction in [18F]FDG-uptake [20, 39-41]. These in vitro experiments thus substantiate our in vivo results of [18F]FLT as the superior early response marker.

The reasons for the observed superiority of [18F]FLT- over [18F]FDG-PET regarding very early assessment of targeted drug therapies remain a matter of debate. It has been suggested that imaging proliferation is a more tumor specific approach being less hampered by inflammatory changes caused by the therapeutic intervention, resulting in non-specific retention of the radiotracer [18F]FDG [17]. Our data suggest a close correlation of the tumoral proliferation fraction and retention of the thymidine analog [18F]FLT also in the early course of cytostatic or cytotoxic therapy. However, the underlying mechanisms may be even more complex, including also DNA repair mechanisms. The influence of DNA repair and other mechanisms related to thymidine metabolism need to be studied in detail in future preclinical studies.

Some limitations have to be considered when transferring our results to the clinic. The number of animals in the experimental arms (very early response after 24 hr and after d + 5/d + 6) significantly differ (n=7 and n=15, respectively). This limitation is related to the fact that the time interval between inoculation of tumor cells and development of local tumors is variable and radiotracers (except [18F]FDG) are not available on a daily basis. This led to the loss of a significant number of animals (n=8) scheduled for the very early assessment of response to treatment. Our results include exclusively in vitro and in vivo data and the findings observed in established sarcoma cell lines and xenotransplant models may not be transferred to the human disease. Despite the preliminary nature of our experiments, further analysis of [18F]FLT-PET also in sarcoma patients seems justified.

In conclusion our data indicate a strong concordance between very early response parameters assessable by [18F]FLT uptake in vivo and in vitro, as confirmed by histological and functional assays. Further studies of [18F]FLT as a very early response marker in clinical trials including patients with sarcoma undergoing targeted cancer drug therapy are therefore highly warranted.

Acknowledgements

We appreciate the excellent support of all members of the technical staff, in particular Sybille Reeder, Elisabeth Aiwanger and Brigitte Dzwjas. This work was supported by the Wilhelm Sander-Stiftung (A. Buck), the Deutsche Forschungsgemeinschaft (U. Keller, A. Beer, M. Schwaiger), and the German Cancer Consortium (DKTK).

Disclosure of conflict of interest

The authors declare that they have no conflict of interest.

Address correspondence to: Dr. Andreas K Buck, Department of Nuclear Medicine, Universitätsklinikum Würzburg, Oberdörrbacher Strasse 6, D-97080 Würzburg, Germany. Tel: +49-931 201-35001; Fax: +49-931 201-635000; E-mail: buck_a@ukw.de

References

[3] Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportuni-
Molecular imaging for sarcoma response assessment


Molecular imaging for sarcoma response assessment


